Emyria Ltd has released a press release.
March 2023 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Emyria
- Emyria launches new high potency Ultra-Pure CBD capsule
- Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
- Emyria to Develop Psilocybin Therapy Care Model
- Emyria agrees licensing and commercialisation deal for EMD-RX5
- Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
Later from Emyria
- Emyria Completes $2.5m Placement
- Emyria Receives Ethics Approval for MDMA-assisted Therapy
- Emyria hails ethics approval for MDMA-assisted clinical trial
- Pax Centre Acquisition to Advance Psychedelic Therapies
- Presentation - Pax Acquisition and Company Update
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria